ThromboGenics (Euronext Brussels: THR) is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer.
Our lead product, ocriplasmin (microplasmin), has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.
Company
ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA®(Ocriplasmin), was approved on October 17, 2012 for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA), otherwise termed vitreomacular traction (VMT). Additionally the Marketing Authorisation Application (MAA) for ocriplasmin has been accepted for review in Europe.
ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon’s net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.
ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the Euronext Brussels exchange under the symbol THR.
More information is available at www.thrombogenics.com.
Job description
Profile
Please apply with your CV and cover letter by the 'apply' button below.
Education Backgrounds: |
Biomedical Science Chemical Engineering Healthcare Science |
Specialties: |
Life sciences Pharmaceutics |
Education Level: |
Doctorate (PH.D) |
Experience: |
2 - 5 years 5 - 10 Years |
Languages spoken: |
English |
Job Location: | Leuven, Belgium |
Type: Job
Deadline: 13th August 2013
Job reference (ID): 5894
Loading...